

### **Remarks**

Claims 1-4, 6, 8, 10-12, 16, 20-28, 32-35, 44, 45, 47, 48, 52, 56 and 67 were pending in this application. Applicants elect Examiner's Group I without traverse (claims 1-4, 6, 8, 10-12, 16, 20, 23-28, 52, 56 and 67) drawn to a humanized CC49 antibody, wherein a L-CDR3 of the humanized CC49 antibody or of a functional fragment of the humanized CC49 antibody comprises a non-conservative amino acid substitution.

### **Conclusion**

It is believed that the application is in condition for substantive examination. If any minor matters remain to be addressed prior to examination, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By /Anne Carlson/  
Anne Carlson, Ph.D.  
Registration No. 47,472